首页> 外文期刊>Human Molecular Genetics >Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers
【24h】

Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers

机译:全基因组关联研究中与乳腺癌相关的常见变异是BRCA1和BRCA2突变携带者中乳腺癌风险的修饰因子

获取原文
           

摘要

Recent studies have identified single nucleotide polymorphisms (SNPs) that significantly modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Since these risk modifiers were originally identified as genetic risk factors for breast cancer in genome-wide association studies (GWASs), additional risk modifiers for BRCA1 and BRCA2 may be identified from promising signals discovered in breast cancer GWAS. A total of 350 SNPs identified as candidate breast cancer risk factors (P < 1 × 10−3) in two breast cancer GWAS studies were genotyped in 3451 BRCA1 and 2006 BRCA2 mutation carriers from nine centers. Associations with breast cancer risk were assessed using Cox models weighted for penetrance. Eight SNPs in BRCA1 carriers and 12 SNPs in BRCA2 carriers, representing an enrichment over the number expected, were significantly associated with breast cancer risk (Ptrend < 0.01). The minor alleles of rs6138178 in SNRPB and rs6602595 in CAMK1D displayed the strongest associations in BRCA1 carriers (HR = 0.78, 95% CI: 0.69–0.90, Ptrend = 3.6 × 10−4 and HR = 1.25, 95% CI: 1.10–1.41, Ptrend = 4.2 × 10−4), whereas rs9393597 in LOC134997 and rs12652447 in FBXL7 showed the strongest associations in BRCA2 carriers (HR = 1.55, 95% CI: 1.25–1.92, Ptrend = 6 × 10−5 and HR = 1.37, 95% CI: 1.16–1.62, Ptrend = 1.7 × 10−4). The magnitude and direction of the associations were consistent with the original GWAS. In subsequent risk assessment studies, the loci appeared to interact multiplicatively for breast cancer risk in BRCA1 and BRCA2 carriers. Promising candidate SNPs from GWAS were identified as modifiers of breast cancer risk in BRCA1 and BRCA2 carriers. Upon further validation, these SNPs together with other genetic and environmental factors may improve breast cancer risk assessment in these populations.
机译:最近的研究已经确定了单核苷酸多态性(SNP),可以显着改变BRCA1和BRCA2突变携带者的乳腺癌风险。由于这些风险调节剂最初在全基因组关联研究(GWAS)中被确定为乳腺癌的遗传风险因素,因此可以从在乳腺癌GWAS中发现的有希望的信号中识别出BRCA1和BRCA2的其他风险调节剂。在来自9个中心的3451个BRCA1和2006 BRCA2突变携带者中,对两项乳腺癌GWAS研究中总共350个SNP确定为候选乳腺癌危险因素(P <1×10 -3 )进行了基因分型。使用权重为Cox模型的外显率评估与乳腺癌风险的相关性。 BRCA1携带者中的8个SNP和BRCA2携带者中的12个SNP,比预期的数量更多,与乳腺癌风险显着相关(P trend <0.01)。 SNRPB中的rs6138178和CAMK1D中的rs6602595的次要等位基因在BRCA1携带者中显示出最强的关联性(HR = 0.78,95%CI:0.69–0.90,P trend = 3.6×10 −4 < / sup>和HR = 1.25,95%CI:1.10-1.41,P 趋势 = 4.2×10 −4 ),而LOC134997中的rs9393597和FBXL7中的rs12652447显示了BRCA2载波中最强的关联(HR = 1.55,95%CI:1.25–1.92,P 趋势 = 6×10 -5 ,HR = 1.37,95%CI:1.16 –1.62,P 趋势 = 1.7×10 -4 )。协会的规模和方向与最初的GWAS一致。在随后的风险评估研究中,基因座似乎对BRCA1和BRCA2携带者的乳腺癌风险呈倍增相互作用。来自GWAS的有希望的候选SNP被确定为BRCA1和BRCA2携带者中乳腺癌风险的修饰因子。经过进一步验证,这些SNP与其他遗传和环境因素一起可以改善这些人群的乳腺癌风险评估。

著录项

  • 来源
    《Human Molecular Genetics》 |2010年第14期|p.2886-2897|共12页
  • 作者单位

    Department of Laboratory Medicine and Pathology and;

    Health Sciences Research, Mayo Clinic, Rochester, MN, USA,;

    Health Sciences Research, Mayo Clinic, Rochester, MN, USA,;

    Health Sciences Research, Mayo Clinic, Rochester, MN, USA,;

    Health Sciences Research, Mayo Clinic, Rochester, MN, USA,;

    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit and;

    Department of Oncology, University of Cambridge, Cambridge, UK,;

    Department of Oncology, University of Cambridge, Cambridge, UK,;

    Department of Oncology, University of Cambridge, Cambridge, UK,;

    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit and;

    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit and;

    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit and;

    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit and;

    Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France,;

    INSERM U509, Service de Génétique Oncologique, Institut Curie, Université Paris-Descartes, Paris, France,;

    Equipe labellisée LIGUE 2008, UMR5201 CNRS, Centre Léon Bérard, Université de Lyon, Lyon, France,;

    INSERM U509, Service de Génétique Oncologique, Institut Curie, Université Paris-Descartes, Paris, France,;

    Department of Pathology, Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands,;

    Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus, The Netherlands,;

    Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands,;

    Queensland Institute of Medical Research, Brisbane, QLD 4029, Australia,;

    Queensland Institute of Medical Research, Brisbane, QLD 4029, Australia,;

    Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany,;

    Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany,;

    Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany,;

    Department of Obstetrics and Gynaecology, Klinikum rechts der Isar, Technical University, Munich, Germany,;

    University of Pennsylvania, Philadelphia, PA, USA,;

    University of Pennsylvania, Philadelphia, PA, USA,;

    University of Pennsylvania, Philadelphia, PA, USA,;

    Medical University of Vienna, Vienna, Austria,;

    Medical University of Vienna, Vienna, Austria,;

    Medical University of Vienna, Vienna, Austria,;

    Medical University of Vienna, Vienna, Austria,;

    Department of Laboratory Medicine and Pathology and;

    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic,;

    Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic,;

    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium,;

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA,;

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA,;

    Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, MA, USA,|Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA and;

    Advanced Technology Center, National Cancer Institute, Gaithersburg, MD, USA;

    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit and;

    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit and;

  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号